American Marconi Wireless News - Genflow Biosciences PLC Announces Recognition of Patentability of Claims

LONDON, UK, AL / ACCESS Newswire / October 20, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), the only publicly listed longevity company in Europe, is pleased to announce that its European patent (No. 22808414.1, Publication No. EP4338267) was officially published in the European Patent Office (EPO) Bulletin on 15 October 2025.

The EPO has recognized the patentability of claims of Genflow's Euro-PCT application, marking a major milestone in the Company's ongoing intellectual property strategy. The European publication number EP4630038 appeared in the Bulletin, signifying that the patent application entered its final pre-grant phase under Article 67(3) EPC. However, Genflow will still need to bring the description into compliance with the claims to respond to this Official Letter; only then will the European Patent Office issue the intention to grant.

With publication, provisional protection took effect across participating EPO member states, allowing Genflow to enforce protection following national validation. This status confirmed the formal recognition of Genflow's application and underscored significant progress toward full patent grant and legal protection across Europe.

Strategic Significance
This publication represents a major step toward securing European patent recognition for key elements of Genflow's longevity gene therapy platform. As the patent enters its final stage before formal recognition, Genflow is positioned to benefit from potential EU grant opportunities and stronger leverage in partnership discussions with pharmaceutical and biotech companies. It also underscores the continued progress in securing the intellectual property backbone of Genflow's SIRT6-based technology across Europe.

Dr. Eric Leire, Chief Executive Officer of Genflow Biosciences, commented: "The publication by the EPO represents a major validation of our scientific innovation and long-term IP strategy. Securing formal European recognition for our patent moves us closer to full protection of our longevity gene therapy platform and strengthens our strategic position for future partnerships and funding opportunities."

Contacts

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there are no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: Genflow Biosciences PLC

View the original press release on ACCESS Newswire

P.Costa--AMWN